Calcitriol - Roche

Drug Profile

Calcitriol - Roche

Alternative Names: Dihydroxycholecalciferol - Roche; Dihydroxyvitamin D3 - Roche; RO 215535; Rocaltrol

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche
  • Developer Chugai Pharmaceutical; Kirin Holdings Company; Roche; Roche Canada; Roche Wien
  • Class Antipsoriatics; Chemoprotectants; Dihydroxycholecalciferols; Osteoporosis therapies; Small molecules; Vitamin D analogues
  • Mechanism of Action Vitamin D3 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Calcium metabolism disorders; Hypocalcaemia; Hypoparathyroidism; Hypophosphataemia; Osteodystrophy; Osteomalacia; Postmenopausal osteoporosis; Rickets; Secondary hyperparathyroidism; Vitamin D deficiency
  • No development reported Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Cancer in USA (SC)
  • 15 Mar 2016 Biomarkers information updated
  • 16 Jun 2008 Fontus Pharmaceuticals acquires Calcitriol from Roche
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top